Is the price fair?
What WGS's price assumes
GeneDx Holdings Corp. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 4.26× revenue.
4.26
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 7.41
Price / book · as of 2026-Q1
- EV / sales
- 4.27
EV / sales
Details›
- Price / book2026-Q1
- 7.41
- EV / EBIToperating margin −15%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 4.27
- Market capitalisation
- $1.75B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #28 of 29 by Smart Score